VERILOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERILOID (VERILOID).
VERILOID is a synthetic alkaloid that acts as a ganglionic blocker, inhibiting nicotinic acetylcholine receptors at autonomic ganglia, leading to reduced sympathetic and parasympathetic outflow. This results in vasodilation and decreased peripheral vascular resistance, lowering blood pressure.
| Metabolism | Primarily hepatic metabolism via unknown pathways; excretion is renal. |
| Excretion | Renal excretion accounts for approximately 60% as unchanged drug; hepatic metabolism contributes 30% with biliary-fecal elimination of metabolites, totaling ~10% fecal. |
| Half-life | Terminal elimination half-life is 3-5 hours, clinically relevant for dose scheduling to maintain steady-state levels. |
| Protein binding | 40-50% bound to albumin. |
| Volume of Distribution | 0.5-0.8 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Oral: 20-30% due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Intravenous: 1-2 minutes; oral: 15-30 minutes. |
| Duration of Action | Intravenous: 0.5-1 hour; oral: 2-4 hours, with rapid offset due to redistribution. |
Intravenous: 0.1-0.5 mg/kg bolus, followed by 0.5-2 mcg/kg/min continuous infusion. Oral: 20-80 mg every 6-8 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 25%. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: use with caution, maximum dose 20 mg per day. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: contraindicated. |
| Pediatric use | Weight-based: 0.05-0.2 mg/kg/dose IV every 6-8 hours, max 10 mg/dose. Continuous infusion: 0.1-0.5 mcg/kg/min. Oral: 0.5-2 mg/kg/day divided every 6-8 hours, max 80 mg/day. |
| Geriatric use | Initiate at 50% of usual adult dose; maximum oral dose 40 mg per day. Monitor for hypotension and bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERILOID (VERILOID).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Use with caution, only if clearly needed. |
| Teratogenic Risk | No human data; animal studies not available. Risk cannot be excluded. Avoid use in first trimester unless essential. Not recommended in pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; assess fetal heart rate and growth if used in pregnancy. |
■ FDA Black Box Warning
None currently; however, due to risk of severe hypotension and adverse effects, its use is limited and not recommended for routine management.
| Serious Effects |
["Hypersensitivity to the drug or its components.","Severe hypotension, shock, or cerebrovascular insufficiency.","Recent myocardial infarction or coronary artery disease.","Renal failure (relative contraindication due to potential accumulation).","Pheochromocytoma (risk of paradoxical hypertension)."]
| Precautions | ["May cause severe orthostatic hypotension, syncope, and dizziness.","Risk of impaired circulation in patients with coronary or cerebral atherosclerosis.","Caution in patients with renal impairment due to accumulation risk.","May worsen symptoms in patients with peptic ulcer disease due to increased gastric secretion.","Abrupt withdrawal may lead to rebound hypertension."] |
Loading safety data…
| Fertility Effects | No human data; animal studies not available. Potential to impair fertility if hypotensive episodes occur. |